IPO Trending
REMUSSME / NSEListed

Remus Pharmaceuticals Limited

Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distribution of pharmaceutical products, including Active Pharmaceutical Ingredients (APIs) and finished formulations in various dosage forms. As of January 31, 2023, the company offers 429 products, with 295 registered in 13 countries and 134 under registration in 16 countries. Remus Pharmaceuticals maintains business-to-business agreements with 58 domestic and 139 international distributors, serving clients across more than 20 countries, including generic distributors, regional distributors, multinational distributors, hospitals, and clinics.

₹1,150 - ₹1,22961.53x sub
Listed Price1711.25
Listing Gain+39.24%
Review-Analyst Consensus Verdict

May apply

No review summary is available yet.

Apply
00%
May Apply
00%
Neutral
00%
Avoid
00%
Not Rated
00%
No IPO review records are available for this issue yet.